Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2017

Price :
Published : Aug-2017
No. of Pages : 50

Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2017


GlobalData’s clinical trial report, “Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2017” provides an overview of Elephantiasis (Lymphatic Filariasis) clinical trials scenario. This report provides top line data relating to the clinical trials on Elephantiasis (Lymphatic Filariasis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

H. Lundbeck AS (LUN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary H. Lundbeck A/S (Lundbeck), a subsidiary of The Lundbeck Foundation carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) related diseases including psychiatric and neurological disorders. Its products are used in the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease among others. The company has production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck's products are sold primarily to pharmaceutical distributors, pharmacies and hospitals. It sells its products in Europe, USA and other countries. Lundbeck is headqua......

Geron Corp (GERN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Ger......

Linde AG (LIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facilities and equipment for gas applications. The company provides gases, therapies, consultation and supporting services for respiratory medicine. It also offers engineering services to petrochemical and chemical industries. . The company serves various sectors including energy, steel, chemical, environmental protection, welding, food processing, glass, electronics and others. It has operations in Europe, North America, AsiaPacific, South America and Africa. Linde is headquartered in Munich, Germ......

Ironwood Pharmaceuticals Inc (IRWD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal (GI) disorders. The company's marketed products consist of Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation in adult men and women; and Zurampic (lesinurad) for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions. Its pipeline product portfolio comprises Duzallo (lesinurad and allopurinol), a combination product for the treatment of hyperuricemia in patients with uncontrolled gout; and other development ......

Teva Pharmaceutical Industries Ltd (TEVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women's health and other therapy areas. The company offers generic medicines in a range of dosage forms, including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, as well as active pharmaceutical ingredients (APIs), the essential raw materials to the drug manufacturing industry. It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a......

Alkermes Plc (ALKS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company's proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, the only once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of product......

ThromboGenics NV (THR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company's ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics's product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has ......

BioTime Inc (BTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company's Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime's products can be used in oncology, neuroscience, orthopedics and blood and vascular disea......

Amgen Inc (AMGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California,......

Omega Pharma NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company's product portfolio includes cough and cold products, skin care products, pain relief products, vitamins, minerals, and nutritional supplements. Its products cater to gastro-intestinal disorders, respiratory issues, eye care, weight management, food supplements, baby care, and skin care. Besides, the company offers auto-diagnostic products such as body temperature meters, ovulation meters and blood pressure meters. It distributes these products to customers through retail distribution and drug store chains. Omega Pharma is headquartered in Naza......